Low Dose of Lenalidomide Enhances NK Cell Activity: Possible Implication as an Adjuvant

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Lenalidomide is a synthetic immunomodulatory drug with anti-angiogenic and anti-proliferative properties.
• It is known to enhance antitumor responses and stimulate Natural Killer (NK) cells.
• Further investigation into lenalidomide's effect on NK cell cytotoxicity in vitro and in vivo is warranted.

Purpose of the Study:

• To evaluate the in vitro impact of varying lenalidomide doses on NK cell cytotoxicity.
• To assess the in vivo adjuvant properties of lenalidomide.

Main Methods:

• NK cell cytotoxicity measured using lactate dehydrogenase (LDH) release assay with K562 cells.
• Lenalidomide tested at 1 mM, 2 mM, 4 mM, and 8 mM concentrations in vitro.
• Adjuvant properties evaluated in mice using a pcDNA3.1(+)/NS3 vaccine model.

Main Results:

• A dose of 4 mMol lenalidomide significantly increased NK cell cytotoxicity in vitro.
• In vivo studies demonstrated lenalidomide stimulated NK cytotoxicity, augmenting it from 16.67% in controls to 38.17% in treated mice.
• Combined treatment with lenalidomide and pcDNA3.1(+)/NS3 improved NK cytotoxicity to 66.80%.

Conclusions:

• Lenalidomide effectively enhances NK cell cytotoxicity both in vitro and in vivo.
• Lenalidomide shows potential as an adjuvant therapy when used with therapeutic vaccines, including cancer and virus vaccines.